Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithium.

ABSTRACT:

Background

The increasing number of cancer survivors, thanks to improved cancer treatments, has escalated the prevalence of adverse effects, especially chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI). New drug classes, including antibody-drug conjugates (ADCs), are being developed to target cancer cells and avoid noxious effects. Despite the efforts, ADCs present a high prevalence of neuropathy. A drug often employed in approved ADCs is Monomethyl Auristatin E (MMAE), a microtubule-based agent. The aim of this study was to investigate the sensory and cognitive effects of MMAE in a mouse model and test the potential use of lithium to alleviate MMAE-induced neuropathy.

Methods

We developed a model of MMAE-induced CIPN and

SUBMITTER: Itaborahy MF 

PROVIDER: S-EPMC12405523 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature